Comments
Loading...
Profound Medical Analyst Ratings and Price Targets | NASDAQ:PROF | Benzinga
Profound Medical Corp has a consensus price target of $12.36 based on the ratings of 6 analysts. The high is $18 issued by TD Cowen on May 11, 2023. The low is $10 issued by Jefferies on March 21, 2023. The 3 most-recent analyst ratings were released by Lake Street, Stifel, and Alliance Global Partners on April 23, 2025, July 16, 2024, and March 11, 2024, respectively. With an average price target of $11.27 between Lake Street, Stifel, and Alliance Global Partners, there's an implied 134.23% upside for Profound Medical Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Lake Street
Stifel
Alliance Global Partners
TD Cowen
Jefferies
1calculated from analyst ratings
Analyst Ratings for Profound Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/23/2025 | Buy Now | 128.69% | Lake Street | Benjamin Haynor27% | $17 → $11 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 149.48% | Stifel | Rick Wise73% | $9 → $12 | Upgrade | Hold → Buy | Get Alert |
| 03/11/2024 | Buy Now | 124.53% | Alliance Global Partners | Ben Haynor37% | $12.75 → $10.8 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 87.11% | Stifel | Rick Wise73% | $11 → $9 | Maintains | Hold | Get Alert |
| 01/04/2024 | Buy Now | 165.07% | Alliance Global Partners | Ben Haynor37% | $14.25 → $12.75 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 128.69% | Stifel | Rick Wise73% | → $11 | Initiates | → Hold | Get Alert |
| 08/04/2023 | Buy Now | — | Raymond James | Rahul Sarugaser20% | — | Downgrade | Strong Buy → Outperform | Get Alert |
| 05/11/2023 | Buy Now | 274.22% | TD Cowen | Joshua Jennings54% | $14 → $18 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 227.44% | Alliance Global Partners | Ben Haynor37% | $13.15 → $15.75 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 107.9% | Jefferies | Michael Sarcone10% | $5.5 → $10 | Downgrade | Buy → Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | — | Raymond James | Rahul Sarugaser20% | — | Upgrade | Outperform → Strong Buy | Get Alert |
FAQ
What is the target price for Profound Medical (PROF) stock?
The latest price target for Profound Medical (NASDAQ:PROF) was reported by Lake Street on April 23, 2025. The analyst firm set a price target for $11.00 expecting PROF to rise to within 12 months (a possible 128.69% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Profound Medical (PROF)?
The latest analyst rating for Profound Medical (NASDAQ:PROF) was provided by Lake Street, and Profound Medical maintained their buy rating.
When was the last upgrade for Profound Medical (PROF)?
The last upgrade for Profound Medical Corp happened on July 16, 2024 when Stifel raised their price target to $12. Stifel previously had a hold for Profound Medical Corp.
When was the last downgrade for Profound Medical (PROF)?
The last downgrade for Profound Medical Corp happened on August 4, 2023 when Raymond James changed their price target from N/A to N/A for Profound Medical Corp.
When is the next analyst rating going to be posted or updated for Profound Medical (PROF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on April 23, 2025 so you should expect the next rating to be made available sometime around April 23, 2026.
Is the Analyst Rating Profound Medical (PROF) correct?
While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a maintained with a price target of $17.00 to $11.00. The current price Profound Medical (PROF) is trading at is $4.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
